Carthera

Today is Glioblastoma Awareness Day. But awareness doesn’t simply mean knowing the facts — that 13,000+ Americans will be diagnosed with glioblastoma this year and that the median survival is nine months — because there is not yet a consistently effective treatment. Awareness means taking time to think about the human stories like Vincent's, impacted by those statistics: patients battling the odds, loved ones navigating unimaginable uncertainty, caregivers working tirelessly, and clinicians fighting for better answers. Today and every day, we’re proud to stand with everyone affected by glioblastoma. And we’re working to advance promising new approaches to give patients, loved ones, caregivers, and clinicians something they urgently deserve: better treatment outcomes, better outcomes, and more reasons to hope. #GBMDay #Glioblastoma #GBM

Many potentially effective drugs for glioblastoma already exist. So why haven’t outcomes improved? The problem is getting them to the tumor: the brain just won’t let them in. The blood-brain barrier is remarkably effective at keeping toxins out. But it also prevents more than 95% of small-molecule drugs and virtually all large-molecule therapies from reaching their targets within the brain. If we can solve the drug delivery problem, we have potential to unlock a new era of brain medicine — not only for glioblastoma, but for many brain diseases where drug delivery remains the greatest challenge.

A glioblastoma diagnosis steals moments. Graduations parents hoped to attend. Birthdays families expected to celebrate. Everyday conversations, holidays, and memories that suddenly become uncertain. This video is a powerful reminder of what those lost moments mean to patients, families, and loved ones. And a reminder of why everyone affected by glioblastoma deserves a better chance — at more time, more milestones, more everyday moments. At Carthera, those moments are what drive our work. We're developing new approaches to glioblastoma treatment with the hope of creating more opportunities for patients to experience the moments that matter most. We're proud to share this powerful message from the National Brain Tumor Society and to stand alongside the patients, families, caregivers, clinicians, and researchers working toward a future where a glioblastoma diagnosis no longer means losing so many meaningful moments. >>> https://lnkd.in/gz9sGSgd

Glioblastoma Awareness Day is July 15 — and it's a chance to rally behind one of the most urgent missions in cancer research today: finding better treatments and, ultimately, a cure for GBM. The reality is stark. Median survival for glioblastoma is just nine months, and more than 13,000 Americans are diagnosed every year. But that's exactly why this work matters so much, and why momentum is building. Researchers, clinicians, and advocates are pushing harder than ever to change those numbers — and every breakthrough brings us closer. On July 15, we're proud to support the National Brain Tumor Society's Glioblastoma Awareness Day and to stand alongside the patients, caregivers, clinicians, researchers, and advocates fueling the search for cures. Together, we're working toward a future where a GBM diagnosis is one of hope — and every person affected by this disease has a better tomorrow.

What if the blood-brain barrier (BBB) wasn't THE major limitation in treating brain tumors and other neurological diseases anymore? How would it change the way patients feel when hearing a brain-related diagnosis? And how would doctors feel being able to offer a treatment plan they know will reach the brain? Better than today. The goal is a tomorrow that is better than today.

Taking part in a clinical trial is an important decision, and one that can raise many questions for patients and their families. It's not always easy to understand the purpose of a study, the different steps involved, the elgibility criteria, or what participation may mean in everyday life. When facing these questions, having access to clear, reliable, and easy-to-understand information is essential. That's why we created a dedicated website for the SONOBIRD clinical trial: to support patients and their loved ones as they explore their options and better understand what participation may involve. Learn more about how the clinical trial works for patients. 🔗 ➡️https://lnkd.in/ghYZQ5u8

Proud to see our Regulatory Affairs Director, Sandra Thiollière, share Carthera’s experience with the EMA's pilot advisory project on orphan medical devices at RAPS Euro Convergence 2026. Sandra shared practical lessons from leading our participation in this pilot project which intends to facilitate the development of innovative devices to treat rare diseases for which no or insufficient alternative therapeutic options exist. A great example of regulatory leadership that helps keep critical innovation moving, especially for small patient populations. Read the full coverage here: https://bit.ly/4xx1eGX

June is Alzheimer's & Brain Awareness Month. For patients and families affected by brain disorders, progress can't come soon enough. Some of the most promising research in neuroscience today centers on new pathways for drug delivery to the brain. Researchers are exploring ways to open a therapeutic window in the blood-brain barrier, enabling promising drug therapies to reliably reach their targets inside the brain. At Carthera, we’re proud to be pushing the leading edge of this exciting frontier in brain medicine. The urgency of this mission drives our work every day. And during Alzheimer's & Brain Awareness Month, we want to specially recognize the researchers, clinicians, caregivers, advocates, patients, and families all working together toward a better future for brain health.

Glioblastoma remains one of the most aggressive brain cancers, with survival rates that have barely changed for decades. We asked Michael Canney, Ph.D. to share why improving drug delivery across the blood-brain barrier may be key to meaningful progress. 👉

Glioblastoma survival rates have been largely unchanged for decades. But the conversation has gradually changed from a lack of promising therapies to whether those therapies will ever reliably reach brain indications. We've moved from a focus on drug discovery (where much of modern medical research lives) to drug delivery. The blood-brain barrier remains one of the toughest obstacles in oncology, shaping outcomes in trials and in care. But what if we could equip doctors with a solution that can help brain indications catch up to where other fields have advanced? Learn more about our pivotal trial in recurrent glioblastoma. 👉 https://sonobird.eu/